FDA extends review for Roche MS drug Ocrevus

ZURICH (Reuters) - Swiss drugmaker Roche said the U.S. Food and Drug Administration (FDA) has extended until March 28 the date for reviewing its application for multiple sclerosis drug Ocrevus.